Clinical Trials Browser

Uveal Melanoma, Melanoma

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT02517736 2026-02-17

O-Mel-Sora

Phase 2 Completed

32 enrolled

Dermatologic

Uveal Melanoma

NCT04552223 2026-02-11

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Phase 2 Completed

27 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT01473004 2025-11-14

SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver

Phase 2 Completed

48 enrolled 10 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT05542342 2025-05-14

SITISVEAL

Phase 2 Completed

16 enrolled

Dermatologic

Uveal Melanoma

NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Phase 2 Completed

14 enrolled 8 charts

Dermatologic

Uveal Melanoma

NCT01355120 2025-04-09

DeCOG

Phase 2 Completed

171 enrolled

Dermatologic

Uveal Melanoma

NCT04417530 2025-03-03

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Phase 2 Completed

22 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT02936388 2025-01-24

SirTac

Phase 2 Completed

108 enrolled

Dermatologic

Uveal Melanoma

NCT01585194 2024-07-09

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 2 Completed

67 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT00445965 2024-04-04

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Phase 2 Completed

78 enrolled 11 charts

CNSDermatologicGynecologicOther solid neoplasmSarcomaThoracic

Familial ependymoma, Uveal Melanoma, Astrocytoma, Brain Neoplasms, Chondrosarcoma, Ependymoma, Glioblastoma, Glioma, Lung Neoplasms, Medulloblastoma, Melanoma, Neoplasm Metastasis, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Glioma, Subependymal, Gliosarcoma, Rhabdoid Tumor, Optic Nerve Glioma, Small Cell Lung Carcinoma, Desmoplastic Small Round Cell Tumor

NCT00020475 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

Dermatologic

Uveal Melanoma, Eye Neoplasms, Neoplasms

NCT02697630 2023-12-08

PEMDAC

Phase 2 Completed

29 enrolled

Dermatologic

Uveal Melanoma

NCT02223819 2023-12-06

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Phase 2 Completed

34 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT03207347 2023-09-15

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Phase 2 Completed

37 enrolled 15 charts

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Phase 2 Completed

47 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT00084656 2022-04-14

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Phase 2 Completed

77 enrolled 13 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT02626962 2022-03-22

GEM1402

Phase 2 Completed

52 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT02129075 2021-11-16

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Phase 2 Completed

60 enrolled 13 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Phase 2 Completed

37 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT01413191 2020-02-19

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

18 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

24 enrolled 10 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT01551459 2019-10-29

SUAVE

Phase 2 Completed

124 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

Phase 2 Completed

98 enrolled 11 charts

Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

NCT01100528 2019-02-26

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Phase 2 Completed

38 enrolled 10 charts

Dermatologic

Uveal Melanoma

NCT00121225 2019-01-29

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Phase 2 Completed

32 enrolled 11 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT01200238 2018-10-18

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Phase 2 Completed

17 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT00243061 2018-08-27

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Phase 2 Completed

24 enrolled 12 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT01961115 2018-06-08

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Phase 2 Completed

11 enrolled 12 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT00450255 2018-05-24

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

41 enrolled 7 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT01034787 2017-10-27

Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

Phase 2 Completed

11 enrolled

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT01252251 2017-08-01

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Phase 2 Completed

14 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

120 enrolled 8 charts

Dermatologic

Uveal Melanoma

NCT00109005 2017-01-02

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

Phase 2 Completed

17 enrolled 11 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT01251978 2016-10-19

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Phase 2 Completed

10 enrolled 7 charts

Dermatologic

Uveal Melanoma

NCT00738361 2016-02-12

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Phase 2 Completed

4 enrolled 7 charts

Dermatologic

Uveal Melanoma

NCT00085306 2015-10-02

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Phase 2 Completed

21 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00089063 2015-04-15

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Phase 2 Completed

40 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00089206 2014-12-19

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Completed

7 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00329641 2014-07-31

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Phase 2 Completed

25 enrolled 6 charts

Dermatologic

Uveal Melanoma

NCT00003339 2014-05-22

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Completed

48 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00031733 2014-05-22

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Phase 2 Completed

60 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00085189 2014-05-22

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Phase 2 Completed

42 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00334776 2014-05-21

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

6 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00096083 2013-10-23

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Phase 2 Completed

56 enrolled

DermatologicEndocrineGastrointestinal

Adenocarcinoma Of Esophagus, Uveal Melanoma, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Melanoma, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Rectal Neoplasms, Somatostatinoma, Stomach Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT00032045 2013-06-20

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Phase 2 Completed

Dermatologic

Uveal Melanoma, Melanoma

NCT00288041 2013-03-05

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Phase 2 Completed

36 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Completed

Dermatologic

Uveal Melanoma, Melanoma

NCT00003802 2012-12-17

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Phase 2 Completed

Dermatologic

Uveal Melanoma, Melanoma

Clinical Trials

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

O-Mel-Sora

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver

SITISVEAL

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

DeCOG

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

SirTac

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

PEMDAC

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

GEM1402

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

SUAVE

Melanoma Vaccine With Peptides and Leuprolide

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma